Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 320

1.

[Who is at risk for drug-drug interactions in type 2 diabetic patients?]

Laurent C, Aho Glele LS, Lazzarotti A, Petit JM, Vergès B, Bouillet B.

Presse Med. 2019 Dec;48(12):1576-1578. doi: 10.1016/j.lpm.2019.09.059. Epub 2019 Nov 21. French. No abstract available.

PMID:
31761604
2.

Physical and Psychological Effectiveness of Cardiac Rehabilitation: Age Is Not a Limiting Factor!

Deley G, Culas C, Blonde MC, Mourey F, Vergès B.

Can J Cardiol. 2019 Oct;35(10):1353-1358. doi: 10.1016/j.cjca.2019.05.038.

PMID:
31601414
3.

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M.

Diabetes Metab. 2019 Sep 17:101117. doi: 10.1016/j.diabet.2019.101117. [Epub ahead of print]

PMID:
31539622
4.

Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.

Brindisi MC, Brondel L, Meillon S, Barthet S, Grall S, Fenech C, Liénard F, Schlich P, Astruc K, Mouillot T, Jacquin-Piques A, Leloup C, Vergès B, Pénicaud L.

Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2489-2494. doi: 10.1016/j.dsx.2019.06.021. Epub 2019 Jun 29.

PMID:
31405666
5.

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.

Fritzen K, Basinska K, Stautner C, Braun KF, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Hosny Y, Schnell O.

J Diabetes Sci Technol. 2019 Aug 6:1932296819864665. doi: 10.1177/1932296819864665. [Epub ahead of print]

PMID:
31387385
6.

A low-carbohydrate high-fat diet initiated promptly after diagnosis provides clinical remission in three patients with type 1 diabetes.

Bouillet B, Rouland A, Petit JM, Vergès B.

Diabetes Metab. 2019 Jul 10. pii: S1262-3636(19)30095-3. doi: 10.1016/j.diabet.2019.06.004. [Epub ahead of print] No abstract available.

PMID:
31301353
7.

Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration but not with visceral fat and liver fat content in people with type 1 diabetes.

Bouillet B, Gautier T, Rouland A, Duvillard L, Petit JM, Lagrost L, Vergès B.

Acta Diabetol. 2019 Oct;56(10):1155-1157. doi: 10.1007/s00592-019-01367-w. Epub 2019 May 22. No abstract available.

PMID:
31119457
8.

Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.

Michiels Y, Bugnon O, Chicoye A, Dejager S, Moisan C, Allaert FA, Hunault C, Romengas L, Méchin H, Vergès B.

Adv Ther. 2019 Jun;36(6):1291-1303. doi: 10.1007/s12325-019-00957-y. Epub 2019 May 2.

9.

CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes.

Bouillet B, Gautier T, Terriat B, Lagrost L, Verges B, Petit JM.

Acta Diabetol. 2019 Jul;56(7):749-754. doi: 10.1007/s00592-019-01340-7. Epub 2019 Apr 12.

PMID:
30980187
10.

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.

Fritzen K, Basinska K, Rubio-Almanza M, Nicolucci A, Kennon B, Vergès B, Zakrzewska K, Schnell O.

J Diabetes Sci Technol. 2019 Nov;13(6):1112-1122. doi: 10.1177/1932296819835172. Epub 2019 Mar 27.

PMID:
30917691
11.

Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction.

Benalia M, Zeller M, Mouhat B, Guenancia C, Yameogo V, Greco C, Yao H, Maza M, Vergès B, Cottin Y.

Diabetes Metab. 2019 Oct;45(5):446-452. doi: 10.1016/j.diabet.2019.01.012. Epub 2019 Feb 11.

PMID:
30763700
12.

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Guerci B, Charbonnel B, Gourdy P, Hadjadj S, Hanaire H, Marre M, Vergès B.

Diabetes Metab. 2019 Dec;45(6):528-535. doi: 10.1016/j.diabet.2019.01.006. Epub 2019 Jan 21. Review.

PMID:
30677504
13.

Depression and obesity, data from a national administrative database study: Geographic evidence for an epidemiological overlap.

Chauvet-Gelinier JC, Roussot A, Cottenet J, Brindisi MC, Petit JM, Bonin B, Vergès B, Quantin C.

PLoS One. 2019 Jan 8;14(1):e0210507. doi: 10.1371/journal.pone.0210507. eCollection 2019.

14.

Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes.

Chauvet-Gélinier JC, Mosca-Boidron AL, Lemogne C, Ragot S, Forestier N, Callegarin D, Allard C, Rebaï A, Bouillet B, Ponavoy E, Simoneau I, Petit JM, Bondolfi G, Callier P, Trojak B, Bonin B, Vergès B.

Diabetes Metab. 2019 Dec;45(6):582-585. doi: 10.1016/j.diabet.2018.11.005. Epub 2018 Nov 23.

15.

Venous thromboembolic events during warm autoimmune hemolytic anemia.

Audia S, Bach B, Samson M, Lakomy D, Bour JB, Burlet B, Guy J, Duvillard L, Branger M, Leguy-Seguin V, Berthier S, Michel M, Bonnotte B.

PLoS One. 2018 Nov 8;13(11):e0207218. doi: 10.1371/journal.pone.0207218. eCollection 2018.

16.

Plasma Renin Concentration is Associated With Hemodynamic Deficiency and Adverse Renal Outcome in Septic Shock.

Nguyen M, Denimal D, Dargent A, Guinot PG, Duvillard L, Quenot JP, Bouhemad B.

Shock. 2019 Oct;52(4):e22-e30. doi: 10.1097/SHK.0000000000001285.

PMID:
30407370
17.

French Endocrine Society Guidance on endocrine side effects of immunotherapy.

Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F.

Endocr Relat Cancer. 2019 Feb;26(2):G1-G18. doi: 10.1530/ERC-18-0320.

18.

Malnutrition in type 2 diabetic patients does not affect healing of foot ulcers.

Rouland A, Fourmont C, Sberna AL, Aho Glele LS, Mouillot T, Simoneau I, Vergès B, Petit JM, Bouillet B.

Acta Diabetol. 2019 Feb;56(2):171-176. doi: 10.1007/s00592-018-1233-9. Epub 2018 Oct 3.

PMID:
30284047
19.

Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.

Wargny M, Ducluzeau PH, Petit JM, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B.

Atherosclerosis. 2018 Nov;278:82-90. doi: 10.1016/j.atherosclerosis.2018.09.008. Epub 2018 Sep 13.

PMID:
30261472
20.

[Is reduction of hyperglycemia associated with a cardiovascular benefit?]

Vergès B.

Presse Med. 2018 Sep;47(9):764-768. doi: 10.1016/j.lpm.2018.08.005. Epub 2018 Sep 12. Review. French.

PMID:
30219206

Supplemental Content

Loading ...
Support Center